(UroToday.com) One of the fastest moving disease spaces in prostate cancer in metastatic castration sensitive prostate cancer. While androgen-deprivation therapy (ADT) alone was the standard treatment five years ago, now there are a number of treatment options that have been shown to improve overall survival, including docetaxel and novel hormonal therapies including abiraterone acetate, enzalutamide, and apalutamide. While these agents have proven benefit in clinical trials, improvement in population-level outcomes depends on their wide-spread adoption. In the Prostate, Testicular, Penile Poster session at the 2021 American Society of Clinical Oncology (ASCO) 2021 Annual Meeting held on Friday June 4th, 2021, Dr. Freedland presented results of an analysis of Medicare data regarding real-world utilization of these agents in men with mCSPC.